NEW YORK, Sept. 29, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced the receipt of a $1.6 million research project cooperative agreement from the National Institutes of Health ("NIH") to accelerate the development of its broad-spectrum antiviral candidates.
